Q2 2023 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2023-08-14 · accession 0000950123-23-008184
$971.0M
Reported value
32
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $150.9M | 15.5% | 3,577,267 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $124.5M | 12.8% | 10,473,913 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $80.8M | 8.32% | 3,081,307 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $73.7M | 7.59% | 4,868,784 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $59.2M | 6.09% | 1,332,548 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $41.5M | 4.28% | 2,305,558 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $37.1M | 3.82% | 11,622,598 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $35.3M | 3.63% | 3,400,000 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $34.1M | 3.51% | 700,197 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $31.2M | 3.21% | 2,415,000 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $31.0M | 3.19% | 15,960,588 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $28.6M | 2.94% | 3,000,000 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $28.5M | 2.94% | 8,663,673 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $27.4M | 2.82% | 2,500,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $25.8M | 2.66% | 2,000,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $20.1M | 2.07% | 5,701,926 | Common | SOLE |
| 26886C107 | — | EQRX INC | $18.6M | 1.92% | 10,003,573 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $18.2M | 1.88% | 1,822,883 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $16.4M | 1.69% | 3,130,422 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $15.5M | 1.60% | 1,431,058 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $14.3M | 1.47% | 1,408,901 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $9.3M | 0.96% | 2,485,638 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $8.4M | 0.87% | 8,434,560 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $7.7M | 0.80% | 2,000,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $7.4M | 0.76% | 2,805,413 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $6.7M | 0.69% | 2,124,694 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $6.4M | 0.66% | 1,921,790 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $4.5M | 0.47% | 1,642,210 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $3.1M | 0.32% | 640,631 | Common | SOLE |
| 140755109 | CARAEUR | CARA THERAPEUTICS INC | $2.6M | 0.27% | 934,898 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $2.0M | 0.21% | 1,937,207 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $209,000 | 0.02% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.